Infinity Pharmaceuticals, Inc. financial data

Location
1100 Massachusetts Avenue, Floor 4, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2023 - Aug 10, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 269 % -52.7%
Debt-to-equity -252 % -163%
Return On Equity 171 %
Return On Assets -113 % -89.5%
Operating Margin -1.64K % +22.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90.8M shares +1.66%
Common Stock, Shares, Outstanding 90.8M shares +1.66%
Common Stock, Value, Issued 90K USD +1.12%
Weighted Average Number of Shares Outstanding, Basic 89.9M shares +0.81%
Weighted Average Number of Shares Outstanding, Diluted 89.9M shares +0.81%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.57M USD +15.9%
Research and Development Expense 27.1M USD -18.6%
General and Administrative Expense 16M USD +12%
Operating Income (Loss) -42M USD +9.92%
Nonoperating Income (Expense) 1.1M USD +413%
Net Income (Loss) Attributable to Parent -40.9M USD +12.5%
Earnings Per Share, Basic 0 USD/shares +11.5%
Earnings Per Share, Diluted 0 USD/shares +11.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.7M USD -61.3%
Other Assets, Current 377K USD -3.09%
Assets, Current 19.9M USD -66.6%
Property, Plant and Equipment, Net 589K USD -42.1%
Operating Lease, Right-of-Use Asset 493K USD -44.4%
Other Assets, Noncurrent 84K USD -54.6%
Assets 21.2M USD -65.7%
Accounts Payable, Current 1.5M USD -17.2%
Employee-related Liabilities, Current 1.22M USD -46.5%
Liabilities, Current 12.1M USD -15.9%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 58.6M USD -6.87%
Retained Earnings (Accumulated Deficit) -877M USD -4.9%
Stockholders' Equity Attributable to Parent -37.4M USD -3279%
Liabilities and Equity 21.2M USD -65.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.6M USD +7.09%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 90.8M shares +1.66%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.6M USD +54.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.9M USD -61.1%
Depreciation 105K USD -13.2%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.9M USD +12.6%
Lessee, Operating Lease, Liability, to be Paid 700K USD -46.2%
Operating Lease, Liability, Current 633K USD +14.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 4.57M USD +43.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%